Avalo Therapeutics, Inc.

AVTX · Nasdaq · United States

Share price · AVTX

$6.70-13.01 (-66.01%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.6M (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AVTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+18.9%
  2. 22 Oct 2026-39.2%
  3. 13 Oct 2026-9.3%
  4. 6 May 2026+34.1%
  5. 5 May 2026+18.0%
  6. 28 Apr 2026-10.8%
  7. 16 Apr 2026+8.0%
  8. 8 Apr 2026-9.5%
  9. 6 Apr 2026-8.4%

    Nothing announced by AVTX that day or the session before.

  10. 1 Apr 2026+11.9%

Share of unusual movement by asset

For each asset, the share of AVTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
abdakibart
events and moves
98%
Other company news (earnings, financing, releases naming no asset)—11%
Sessions with no dated event—80%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
IL-1 betaMonoclonal antibody
Hidradenitis Suppurativa
QuisovalimabNo recent activity
Phase 2
LIGHT (TNFSF14)Monoclonal antibody
Asthma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 May 2026Topline resultabdakibartPhase 2 LOTUS (NCT06603077) of abdakibart in hidradenitis suppurativa met its primary endpoint
Avalo Therapeutics, Inc. · Source ↗
26 June 2023Topline resultQuisovalimabPhase 2 PEAK topline: primary endpoint not met
Avalo Therapeutics · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$15M$65M+ $328M short-term inv.$19M-$12M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$23M$86M+ $315M short-term inv.$36M-$20M operating cash flowreport ↗
2026-Q1—$14M$25M+ $57M short-term inv.$20M-$18M operating cash flowreport ↗
2025-Q3$0$14M$27M+ $85M short-term inv.$31M-$16M operating cash flowreport ↗
2025-Q2—$14M$43M+ $71M short-term inv.$21M-$11M operating cash flowreport ↗
2025-Q1—$9.1M$125M$13M-$9.5M operating cash flowreport ↗
2024-Q3$0.3M$9.5M$82M—-$12M operating cash flowreport ↗
2024-Q2$0$4.6M$94M—-$16M operating cash flowreport ↗
2024-Q1$0$2.1M$110M$121M-$6.2M operating cash flowreport ↗
2023-Q3$0.2M$1.3M$10M$5.2M-$6.8M operating cash flowreport ↗
2023-Q2$0.6M$4.7M$6.5M$8.2M-$11M operating cash flowreport ↗
2023-Q1$0.5M$6.0M$17M$10.0M-$10M operating cash flowreport ↗
2022-Q3$15M$7.0M$17M—$5.7M operating cash flowreport ↗
2022-Q2$1.0M$8.5M$11M$13M-$12M operating cash flowreport ↗
2022-Q1$1.2M$9.6M$39M$22M-$16M operating cash flowreport ↗
2021-Q3$1.4M$11M$72M$17M-$16M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.1M$50M$16M+ $82M short-term inv.$20M-$51M operating cash flowreport ↗

Avalo Therapeutics reported FY2025 revenue of $0.06M, down 86.4% YoY, and R&D expenditures of $50.08M, up 104.9% YoY. Cash, cash equivalents and short-term investments totaled $98.3M at December 31, 2025, and the company reported a net loss of $78.26M for the year.

Management stated that current cash, cash equivalents and short-term investments are expected to fund operations into 2028. The key upcoming milestone is topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) in hidradenitis suppurativa, expected in the second quarter of 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.4M$24M$135M+ $0 short-term inv.$8.8M-$49M operating cash flowreport ↗
2023-FY$1.9M$14M$7.5M$7.9M-$31M operating cash flowreport ↗
2022-FY$18M$31M$13M$10M-$27M operating cash flowreport ↗
2021-FY$5.4M$60M$55M$21M-$71M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 41 sales ($8.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-30Philip Ron M · directorAward / grant (derivative)1,109$12.29$14KForm 4
2026-09-30Lind Kevin Robert · directorAward / grant (derivative)1,352$12.29$17KForm 4
2026-09-30Jain Rita · directorAward / grant (derivative)1,322$12.29$16KForm 4
2026-09-16Sullivan Christopher Ryan · Chief Financial OfficerOption exercise12,394$9.88$122KForm 4
2026-09-16Sullivan Christopher Ryan · Chief Financial OfficerOpen-market sale12,394$16.33$202KForm 4
2026-09-16Sullivan Christopher Ryan · Chief Financial OfficerOption exercise (derivative)12,394——Form 4
2026-09-10Sullivan Christopher Ryan · Chief Financial OfficerOption exercise10,185$8.04$82KForm 4
2026-09-10Sullivan Christopher Ryan · Chief Financial OfficerOpen-market sale10,185$17.62$179KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 97 reporting institutions held 31.2M shares ($433.2M, 54.0% of shares outstanding).

#InstitutionSharesValue
1FMR LLC2,879,481$43.0M
2Caligan Partners LP1,635,023$24.4M
3BVF INC/IL1,632,845$24.4M
4Avoro Capital Advisors LLC1,410,000$21.1M
5Affinity Asset Advisors, LLC1,340,840$20.0M
6Nantahala Capital Management, LLC1,235,000$18.4M
7UBS Group AG1,141,980$17.0M
8Point72 Asset Management, L.P.916,142$13.7M
9FARALLON CAPITAL MANAGEMENT LLC916,000$13.7M
10RTW INVESTMENTS, LP856,962$12.8M
11ADAGE CAPITAL PARTNERS GP, L.L.C.854,000$12.8M
12MILLENNIUM MANAGEMENT LLC835,484$12.5M
13TCG Crossover Management, LLC738,383$11.0M
14Balyasny Asset Management L.P.731,586$10.9M
15VANGUARD CAPITAL MANAGEMENT LLC719,694$10.7M